ApexOnco

1 week ago | oncologypipeline.com | Madeleine Armstrong

TAK-280 is among the group's discarded projects, although it’s a T-cell engager, not an ADC. B7-H3 is a hot target, but it’s now one that Takeda won’t be pursuing. The company disclosed in its full-year earnings on Thursday that it discontinued TAK-280, which hits B7-H3; however, recent successes have come with ADCs, and the Takeda asset is a T-cell engager. More predictably, the Japanese group is also abandoning the Sting agonist dazostinag; this mechanism has had its fair share of failure.

1 week ago | oncologypipeline.com | Madeleine Armstrong

The group’s latest update focused on new data with the KRAS G12C inhibitor elironrasib. Revolution Medicines is most famous for its pan-RAS inhibitor daraxonrasib, but during its first-quarter earnings, released after market on Wednesday, the company released a rash of new data mostly concerning its KRAS G12C contender, elironrasib.

1 week ago | oncologypipeline.com | Madeleine Armstrong

Dellphi-312, testing Imdelltra plus PD-(L)1, will start mid-year. Amgen, fresh from a phase 3 win in second-line small-cell lung cancer, is taking its DLL3-targeting T-cell engager Imdelltra into untreated disease. The company said last week during its first-quarter earnings that it would start the first-line Dellphi-312 study by mid-year. There aren’t many details yet on trial design, but Amgen plans to combine Imdelltra with chemo and AstraZeneca’s checkpoint inhibitor Imfinzi.

1 week ago | oncologypipeline.com | Madeleine Armstrong

Conference activity picks up, with the big one – ASCO – at the end of the month. It might be doom and gloom in the biopharma industry right now, but summer is coming, along with the big oncology conference of the year: ASCO. So far, only the abstract titles have been released, but non-late-breaking abstracts are set to drop on 22 May.

1 week ago | oncologypipeline.com | Madeleine Armstrong

So far B7-H4 hasn't convinced as a target, but Mersana is now putting all its hopes here, following a cost-cutting exercise announced Tuesday. Specifically, the company is focusing its ADC emiltatug ledadotin on triple-negative breast cancer, where the project produced a 23% ORR in phase 1 – albeit in a curated dataset that involved just 13 B7-H4-high patients receiving “intermediate” doses of 38.1-67.4mg/m2.